<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287414</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736X2207</org_study_id>
    <nct_id>NCT03287414</nct_id>
  </id_info>
  <brief_title>Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and efficacy of VAY736 administered subcutaneously&#xD;
      (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1&#xD;
      ratio on top of local standard of care (SOC), to receive VAY736 or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">October 5, 2022</completion_date>
  <primary_completion_date type="Actual">November 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A subject-, investigator-, and sponsor-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to end of treatment epoch (48 weeks of treatment) in Forced Vital Capacity (FVC).</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>To assess the efficacy of VAY736 in patients with idiopathic pulmonary fibrosis Change from baseline to end of treatment epoch (48 weeks of treatment) in Forced Vital Capacity (FVC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-Cause mortality</measure>
    <time_frame>Week 48</time_frame>
    <description>To assess the impact of VAY736 on survival: All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Week 48</time_frame>
    <description>Progression free survival analysis as defined will be produced at the end of the treatment epoch (week 48) for the following event of interest:&#xD;
Events, defined as: death (all-cause mortality) OR &quot;progression&quot; (relative reduction in FVC ≥ 10%)&#xD;
Events, defined as: death (IPF-related mortality) OR &quot;progression&quot; (relative reduction in FVC ≥ 10%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Week 48</time_frame>
    <description>Disease Progression, defined as: a)relative reduction in FVC ≥ 10% b) relative reduction in Diffusing Capacity of the Lungs (DLCO) ≥ 15% c) absolute reduction in Six Minute Walk Distance (6MWD) ≥ 50 m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint</measure>
    <time_frame>Week 48</time_frame>
    <description>Composite Endpoint defined as:&#xD;
death (all-cause mortality), OR relative reduction in FVC≥10%, OR relative reduction in DLCO ≥15%, OR relative reduction in 6MWD ≥50m&#xD;
death (IPF-related morality), OR relative reduction in FVC≥10%, OR relative reduction in DLCO ≥15%, OR relative reduction in 6MWD ≥50m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of treatment epoch (Week 48) in Diffusing Capacity of the Lungs (DLCO)</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>To assess the impact of VAY736 on Pulmonary Physiology: Change from baseline to theend of treatment epoch (week 48) in DLCO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the end of treatment epoch (Week 48) in 6-minute walk test and in distance-saturation product</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline to the end of treatment epoch (Week 48) in 6-minute walk test and in distance-saturation product to assess the impact of VAY736 on exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the end of treatment epoch (Week 48) in resting oxygen saturation (on room air)</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline to the end of treatment epoch (Week 48) in resting oxygen saturation (on room air) to assess the impact of VAY736 on gas exchange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of VAY736</measure>
    <time_frame>Week 48</time_frame>
    <description>To assess the immunogenicity of VAY736 by measuring Serum anti-VAY736 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics Cmin,ss of VAY736 after multiple s.c. doses</measure>
    <time_frame>Day 1 through Week 69</time_frame>
    <description>Determine the Cmin,ss from the serum concentration (VAY736)-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Idiopathic Pulmonary Fibrosis (IPF) -related Mortality</measure>
    <time_frame>Week 48</time_frame>
    <description>To assess the impact of VAY736 on survival: IPF-related mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>VAY736</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 administered subcutaneously (s.c.) every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously (s.c.) every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <description>VAY736 administered subcutaneously (s.c.) every 4 weeks</description>
    <arm_group_label>VAY736</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered s.c. every 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care (SoC)</intervention_name>
    <description>nintedanib, pirfenidone, or neither</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>VAY736</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of definite or probable IPF within 5 years of the screening visit, as&#xD;
             defined by Figure 3, Tables 4-6 of the ATS/ERS/JRS/ALAT Diagnostic Guidelines (Raghu&#xD;
             et al 2011)&#xD;
&#xD;
          2. FVC 40-90% predicted (inclusive)&#xD;
&#xD;
          3. DLCO, corrected for hemoglobin, 25-79% predicted (inclusive)&#xD;
&#xD;
          4. FEV1/FVC &gt;70%&#xD;
&#xD;
          5. Unlikely to die from cause other than IPF within the next 3 years, in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          6. Unlikely to undergo lung transplantation during this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Emphysema &gt; fibrosis on screening HRCT (must be confirmed by central reader)&#xD;
&#xD;
          2. History of major organ, hematopoietic stem cell or bone marrow transplant&#xD;
&#xD;
          3. Clinically diagnosed AE-IPF or other significant clinical worsening within 3 months of&#xD;
             randomization&#xD;
&#xD;
          4. New York Heart Association (NYHA) class III/IV Congestive Heart Failure (CHF),&#xD;
             Ejection Fraction (EF) &lt;25%&#xD;
&#xD;
          5. Current smoker&#xD;
&#xD;
          6. Prior use of any B-cell depleting therapy (e.g., rituximab, ofatumumab, or other&#xD;
             anti-CD20 mAb, anti-CD40, anti-CD19,anti-CD22 mAb, anti-CD52 mAb, or anti-BAFF mAb)&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coswig</city>
        <zip>01640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>D04</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Forli</city>
        <state>Forli - Cesena</state>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Heaton</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <disposition_first_submitted>October 26, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>October 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 28, 2021</disposition_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <keyword>VAY736</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

